तुलना करने के लिए मीट्रिक्स | AZTR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधAZTRपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.3x | −11.7x | −0.5x | |
PEG अनुपात | 0.00 | −0.03 | 0.00 | |
क़ीमत/बुक | 0.3x | 2.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 6.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 79.2% | 55.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.8% | 9.7% | अनलॉक करें |
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.